![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
DRUG PROFILE OF SOFOSBUVIR - A NUCLEOTIDE ANALOG INHIBITOR OF THE HEPATITIS C VIRUS POLYMERASE
V.R.Ghayathri *, C.Vinodhini, S.Gayatri, K.Chitra
ABSTRACT Sofosbuvir is the drug of choice for hepatitis C virus (HCV) infection, with a high cure rate. Sofosbuvir is a component of the first all-oral, interferon-free regimen approved by FDA for treatment of chronic hepatitis C. It inhibits the RNA polymerase that the hepatitis C virus uses to replicate its RNA. This review describes the drug profile of sofosbuvir that may recommend major treatment advantages over live benefits. Keywords: Sofosbuvir, Hepatitis C , GS 331007 , FDA [Download Article] [Download Certifiate] |